Melatonin Protects Myocardium from Ischemia-Reperfusion Injury in Hypertensive Rats: Role of Myeloperoxidase Activity

References

• Ogita H, Liao J. Endothelial function and oxidative stress. Endothelium 2004; 11: 123–132
   PubMed Web of Science ®Google Scholar
• Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?. Hypertension. 2004; 44: 248–252
   PubMed Web of Science ®Google Scholar
• Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM. García-Redondo A, Beltrán A, Alonso MJ, Salaices M. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther. 2007; 321: 381–388
   PubMed Web of Science ®Google Scholar
• Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: Protective effects of melatonin. J Pineal Res. 2008; 44: 16–25
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Des. 2004; 10: 1695–1698
   PubMed Web of Science ®Google Scholar
• Sahna E, Parlakpinar H, Turkoz Y, Acet A. Effects of melatonin on myocardial ischemia-reperfusion-induced infarct size and oxidative stress. Physiol Res. 2005; 54: 491–495
   PubMed Web of Science ®Google Scholar
• Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: Can the incidence of sudden cardiac death be reduced?. J Pineal Res. 2002; 32: 194–198
   PubMed Web of Science ®Google Scholar
• Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: Roles, mechanisms, and therapeutic implications. Pharmacol Therap. 2001; 89: 187–206
   PubMed Web of Science ®Google Scholar
• Bernatova I, Pechanova O, Simko F. Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res. 1996; 45: 311–316
   PubMed Web of Science ®Google Scholar
• Kanematsu Y, Tsuchiya K, Ohnishi H, Motobayashi Y, Izawa Y, Ishihara M, Ishizawa K, Abe S, Kawazoe K, Tamaki T. Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nω-nitro-L-arginine methyl ester-treated rats. Hypertens Res. 2006; 29: 369–374
   PubMed Web of Science ®Google Scholar
• Pechanova O, Bernatova I, Babal P, Martinez MC, Kysela S, Stvrtina S, Andriantsitohaina R. Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens. 2004; 22: 1551–1559
   PubMed Web of Science ®Google Scholar
• Deniz E, Colakoglu N, Sari A, Sonmez MF, Tugrul I, Oktar S, Ilhan S, Sahna E. Melatonin attenuates renal ischemia-reperfusion injury in nitric oxide synthase inhibited rats. Acta Histochem. 2006; 108: 303–309
   PubMed Web of Science ®Google Scholar
• Liu P, Xu B, Forman LJ, Carsia R, Hock CE. L-NAME enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock. 2002; 17: 185–192
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX. Melatonin: A novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovascular Res. 2003; 58: 10–19
   PubMed Web of Science ®Google Scholar
• Sahna E, Deniz E, Aksulu HE. Myocardial ischemia-reperfusion injury and melatonin. Anadolu Kardiyol Derg. 2006; 6: 163–168
   PubMedGoogle Scholar
• Sener G, Sehirli AO, Ayanoglu-Dulger G. Melatonin protects against mercury (II)-induced oxidative tissue damage in rats. Pharmacol Toxicol. 2003; 93: 290–296
   PubMedGoogle Scholar
• Girouard H, Denault C, Chulak C, de Champlain J. Treatment by n-acetylcysteine and melatonin increases cardiac baroreflex and improves antioxidant reserve. Am J Hypertens. 2004; 17: 947–954
   PubMed Web of Science ®Google Scholar
• Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels and blood pressure in healthy men. Am J Cardiol. 1999; 83: 1417–1419
   PubMed Web of Science ®Google Scholar
• Pechanova O, Zicha J, Paulis L, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol. 2007; 561: 129–136
   PubMed Web of Science ®Google Scholar
• Deniz E, Sahna E, Aksulu HE. Nitric oxide synthase inhibition in rats: Melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size. Scandinavian Cardiovascular Journal. 2006; 40: 248–252
   PubMed Web of Science ®Google Scholar
• Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods. 1985; 14: 157–167
   PubMedGoogle Scholar
• Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by tiobarbituric acid test. Anal Biochem. 1978; 34: 271–278
   Web of Science ®Google Scholar
• Fairbanks V, Klee GG. Biochemical aspects of hematology. Textbook of Clinical Chemistry, NW Tietz. W.B. Saunders, Philadelphia 1986; 1532–1534
   Google Scholar
• Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflamation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982; 78: 206–209
   PubMed Web of Science ®Google Scholar
• Husain K. Interaction of exercise training and chronic NOS inhibition on blood pressure, heart rate, NO and antioxidants in plasma of rats. Pathophysiology. 2003; 10: 47–56
   PubMedGoogle Scholar
• Chuang JI, Chen SS, Lin MT. Melatonin decreases brain serotonin release, arterial pressure, and heart rate in rats. Pharmacology. 1993; 47: 91–97
   PubMed Web of Science ®Google Scholar
• Girouard H, Chulak C, Lejossec M, Lamontagne D, de Champlain J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens. 2001; 19: 1369–1377
   PubMed Web of Science ®Google Scholar
• Birau N, Peterssen U, Meyer C, Gottschalk J. Hypotensive effect of melatonin in essential hypertension. IRCS Med Sci 1981; 9: 906
   Google Scholar
• Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000; 109: 315–323
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 31–47
   PubMed Web of Science ®Google Scholar
• Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: Role of bradykinin and nitric oxide. Hypertens Res. 2000; 23: 253–259
   PubMed Web of Science ®Google Scholar
• Entman ML, Smith CW. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994; 9: 1301–1311
   Google Scholar
• Lefer J, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol. 1999; 276: 1943–1950
   PubMed Web of Science ®Google Scholar
• Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxic shock. Cardiovasc Res 1992; 26: 48
   PubMed Web of Science ®Google Scholar
• Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 2003; 285: 59–64
   Web of Science ®Google Scholar
• Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004; 37: 902–911
   PubMed Web of Science ®Google Scholar
• Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation. 1993; 88: 2337–2350
   PubMed Web of Science ®Google Scholar